Description

What is Belviq 10mg?

Belviq 10mg is sometimes used to treat obesity that may be related to diabetes, high cholesterol, or high blood pressure.

Belviq 10mg is designed to help you feel full after you’ve eaten less food. This medication activates serotonin receptors in your brain. The serotonin receptors regulate hunger. When they signal your body to feel full, you may be able to eat less and lose weight.

Dosage

The regular tablet is usually taken 2 times per day. The extended-release tablet is taken only once per day. Follow your doctor’s instructions.

Do not crush, chew, or break an extended-release tablet. Swallow it whole.

You may take Belviq with or without food.

You should lose at least 5% of your starting weight during the first 12 weeks of taking Belviq and eating a low calorie diet. Call your doctor if you do not lose at least 5% of your starting weight after taking the medicine for 12 weeks.

Belviq is only part of a complete program of treatment that also includes diet, exercise, weight control, and possibly testing your blood sugar. Follow your diet, medication, and exercise routines very closely.

Store at room temperature away from moisture and heat.

Keep track of the amount of medicine used from each new bottle. Lorcaserin is a drug of abuse and you should be aware if anyone is using your medicine improperly or without a prescription.

Side effects Belviq 10mg

The following important adverse reactions are described below and elsewhere in labeling:

• Serotonin Syndrome or NMS-like Reactions
• Valvular Heart Disease
• Cognitive Impairment
• Psychiatric Disorders
• Hypoglycemia
• Heart Rate Decreases
• Hematological Changes
• Prolactin Elevation

Most Common Adverse Reactions

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The most common adverse reactions for non-diabetic patients (greater than 5% and more commonly than placebo) treated with BELVIQ compared to placebo were headache, dizziness, fatigue, nausea, dry mouth, and constipation. The most common adverse reactions for diabetic patients were hypoglycemia, headache, back pain, cough, and fatigue. Adverse reactions that were reported by greater than or equal to 2% of patients and were more frequently reported by patients taking BELVIQ compared to placebo are summarized in Table 2 (non-diabetic subjects) and Table 3 (subjects with type 2 diabetes mellitus).